Anita Mamtani, MD, on Axillary Dissection: For What Types of Breast Cancer Can It Be Avoided?
2023 Society of Surgical Oncology International Conference on Surgical Cancer CareAnita Mamtani, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings showing that axillary lymph node dissection was required by less than 2% of patients with cT1NO triple-negative or HER2-positive breast cancer having upfront surgery. There was no clear advantage of neoadjuvant chemotherapy in reducing the risk of lymph node dissection in this cohort. Upfront surgery is a suitable approach in these patients, says Dr. Mamtani, allowing for de-escalated chemotherapy regimens in patients with pathologic node-negative disease. (Abstract P1).